Breakthrough Designations Announced By Companies (Updated 5/6/2015):
As of April 13, 2015, FDA has given 23* approvals to drugs designated as Breakthrough Therapies, 13 of them first time approvals for novel drugs. FDA-approved drugs are highlighted in green in the below table. Drugs for which the Breakthrough designation has been rescinded are highlighted in red.
* Chart represents designations that have been announced by their sponsors
Working with our partners in all sectors, Friends took ‘Breakthrough’ from concept, to scientific whitepaper, to bipartisan legislative solution, to a tool in full use by FDA to expedite the approval of multiple drugs in 13 months.
On November 1, 2013, only a year after being signed into law, and 29 designations being announced, the first Breakthrough designation received full FDA Approval.
Here is a list of 2013's Breakthrough designations and approvals. Twelve of the year's 28 publicly announced designations were for cancer drugs, as well as two of its three Breakthrough approvals.
As knowledge about complex disease such as cancer and HIV/AIDS has expanded, researchers have been able to develop increasingly precise methods of treatment. Targeted therapies, a variety of drugs that targets specific molecular pathways, allow physicians and researchers to identify patients highly likely to respond to treatment. Frequently, these new drugs show major clinical activity and significant improvement over currently available treatment early in their development. In cases where new drugs show so much promise, and particularly in cases where existing treatment options are limited, the traditional multi-phase, sequential drug development process may not be appropriate.
Breakthrough Therapy (and Friends) in the News
FRIENDS OF CANCER RESEARCH
1800 M Street NW Suite 1050 | Washington, DC 20036